| Literature DB >> 34277318 |
Maria V Ermoshchenkova1,2,3, Aziz D Zikiryahodjaev1,2, Igor V Reshetov2, Dmitriy S Svyatoslavov2, Mikhail Y Sinelnikov1,4.
Abstract
BACKGROUND: Patients who undergo breast cancer treatment require psychosocial and aesthetic rehabilitation. Advantages of breast reconstruction in-patient rehabilitation are well known. Oncoplastic organ-preserving surgery offers aesthetically better results, yet is often considered less safe than more radical procedures. We compared the aesthetic and psychological outcomes in patients undergoing breast reconstruction and oncoplastic breast cancer treatment.Entities:
Year: 2021 PMID: 34277318 PMCID: PMC8277256 DOI: 10.1097/GOX.0000000000003679
Source DB: PubMed Journal: Plast Reconstr Surg Glob Open ISSN: 2169-7574
Immunohistochemical Characteristics of Patient Pathology
| Immunohistochemical Tumor Type | No. Cases | % |
|---|---|---|
| Luminal type А | 558 | 44.64 |
| Luminal type В, Her-2/neu- negative | 168 | 13.44 |
| Luminal type B В, Her-2/neu- positive | 321 | 25.68 |
| HER-2/neu-positive | 68 | 5.44 |
| Triple negative | 135 | 10.8 |
| Total | 1250 | 100 |
Overall Study Characteristics and Results
| Group 1 | Group 2 | ||
|---|---|---|---|
| Simultaneous Breast Reconstruction | Oncoplastic Resection | ||
| Overall No. Cases | 510 | 620 | |
| Age, y (mean) | 44 ± 8.48 | 54.3 ± 10.2 | 0.438 |
| Follow-up, mo (mean) | 49.2 ± 8.3 | 44.5 ± 12.3 | 0.751 |
| Premenopausal | 349 (68.43%) | 189 (30.48%) | <0.001 |
| Postmenopausal | 161 (31.57%) | 431 (69.52%) | <0.001 |
| Stage 0 | 25 (4.90%) | 26 (4.19%) | 0.569 |
| Stage I | 156 (30.59%) | 330 (53.23%) | <0.001 |
| Stage IIA | 146 (28.63%) | 172 (27.74%) | 0.742 |
| Stage IIB | 75 (14.70%) | 37 (5.97%) | <0.001* |
| Stage IIIA | 69 (13.53%) | 31 (5.00%) | <0.001 |
| Stage IIIB | 21 (4.12%) | 21 (3.39%) | 0.519 |
| Stage IIIC | 17 (3.33%) | 3 (0.48%) | <0.001 |
| Stage IV | 1 (0.019%) | 0 (0.00%) | 0.270 |
| Neoadjuvant chemotherapy | 122 (23.92%) | 39 (6.29%) | <0.001 |
| Luminal A | 199 (39.02%) | 307 (49.52%) | <0.001 |
| Luminal B, HER-2/neu positive | 75 (14.71%) | 77 (12.42%) | 0.263 |
| Luminal B, HER-2/neu negative | 102 (2.00%) | 178 (28.7%) | <0.001 |
| Nonluminal | 42 (8.24%) | 23 (3.7%) | 0.002 |
| Triple negative | 87 (17.06%) | 34 (5.48%) | <0.001 |
| Hospitalization stay (days, mean) | 12.79 ± 7.32 | 10.32 ± 4.77 | 0.777 |
| Expander-implant reconstruction (n) | 236 (46.27%) | N/A | N/A |
| Direct to implant reconstruction (n) | 212 (41.57%) | ||
| DIEP flap (n) | 12 (23.53%) | ||
| TRAM flap (n) | 34 (66.67%) | ||
| Thoracodorsal flap with implant (n) | 16 (31.37%) | ||
| Contralateral mammoplasty (n) | 66 (12.94%) | 98 (15.81%) | 0.244 |
| Lipofilling (n) | 41 (8.04%) | 6 (0.97%) | <0.001 |
| Seroma | 31 (6.08%) | 7 (1.13%) | <0.001 |
| Skin necrosis | 18 (3.53%) | 2 (3.23%) | <0.001 |
| Suture dehiscence | 21 (4.12%) | 8 (1.30%) | 0.003 |
| Infection | 7 (1.37%) | 0 (0.00%) | 0.004 |
| Implant-related complications | 96 (18.82%) | N/A | N/A |
| Surgical revision rate | 48 (9.41%) | 6 (0.97%) | <0.001 |
| Cancer recurrence | 10 (1.96%) | 7 (1.13%) | 0.254 |
| Cancer progression | 21 (4.12%) | 9 (1.45%) | 0.006 |
| Aesthetic result (grade) | 4.2 ± 0.04 | 4.8 ± 0.05 | <0.001 |
| Psychosocial impact (grade) | 3.3 ± 0.04 | 4.6 ± 0.06 | <0.001 |
Statistically significant at P < 0.05.